Betahydroxyfentanyl

Betahydroxyfentanyl

Systematic (IUPAC) name
N-[1-(2-hydroxy-2-phenylethyl)piperidin-4-yl]-N-phenylpropanamide
Clinical data
Legal status	CA: Schedule I DE: Anlage I (Controlled) UK: Class A US: Schedule I
Identifiers
CAS Number	78995-10-5
ATC code	none
PubChem	CID: 62278
DrugBank	DB01453 Y
ChemSpider	56079 Y
UNII	6Q4XAW26T4 Y
Synonyms	β-hydroxyfentanyl
Chemical data
Formula	C22H28N2O2
Molecular mass	352.47 g/mol
SMILES O=C(N(c1ccccc1)C3CCN(CC(O)c2ccccc2)CC3)CC
InChI InChI=1S/C22H28N2O2/c1-2-22(26)24(19-11-7-4-8-12-19)20-13-15-23(16-14-20)17-21(25)18-9-5-3-6-10-18/h3-12,20-21,25H,2,13-17H2,1H3 Y Key:JEFVHLMGRUJLET-UHFFFAOYSA-N Y
(verify)

β-Hydroxyfentanyl is an opioid analgesic that is an analogue of fentanyl.

β-hydroxyfentanyl was sold briefly on the black market in the early 1980s, before the introduction of the Federal Analog Act which for the first time attempted to control entire families of drugs based on their structural similarity rather than scheduling each drug individually as they appeared.

β-hydroxyfentanyl has similar effects to fentanyl. Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.